Patents Assigned to AVANTI POLAR LIPIDS, INC.
  • Patent number: 10739353
    Abstract: The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 11, 2020
    Assignees: Signpath Pharma, Inc., Avanti Polar Lipids, Inc.
    Inventors: Peter P. Sordillo, Lawrence Helson, Stephen W. Burgess, Walter A. Shaw
  • Patent number: 10463738
    Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: November 5, 2019
    Assignee: Avanti Polar Lipids, Inc.
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li
  • Patent number: 10143744
    Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: December 4, 2018
    Assignees: Avanti Polar Lipids, Inc, AC Immune SA
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
  • Patent number: 9872908
    Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: January 23, 2018
    Assignee: Avanti Polar Lipids, Inc.
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li
  • Patent number: 9518078
    Abstract: Essentially pure compounds of the formulas (I) to (XXV) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: December 13, 2016
    Assignees: Avanti Polar Lipids, Inc., AC Immune SA
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
  • Patent number: 9403760
    Abstract: Disclosed are compounds of the general formula I and II (as further defined herein) are useful in the production of inhibitors of sphingolipid synthesis the production of sphingolipids. Suitable sphingolipids, include, but not limited to, sphingosine and compounds incorporating sphingosine or that may use sphingosine as an intermediate or a starting material in their synthesis (including, but not limited to, sphingosine-1-P, ceramide, gangliosides and sphingomyelin). In one contemplated use, compounds of the general formula I and II are useful in the production of sphingosine. In another contemplated use, compounds of the general formula I and II are useful in the production of a sphingofugin. Methods of manufacturing each of the above compounds are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 2, 2016
    Assignee: AVANTI POLAR LIPIDS, INC.
    Inventors: Stephen W Burgess, Walter A Shaw, Shengrong Li
  • Patent number: 9241988
    Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 26, 2016
    Assignees: AVANTI POLAR LIPIDS, INC., AC IMMUNE SA
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
  • Publication number: 20140275591
    Abstract: Disclosed are compounds of the general formula I and II (as further defined herein) are useful in the production of inhibitors of sphingolipid synthesis the production of sphingolipids. Suitable sphingolipids, include, but not limited to, sphingosine and compounds incorporating sphingosine or that may use sphingosine as an intermediate or a starting material in their synthesis (including, but not limited to, sphingosine-1-P, ceramide, gangliosides and sphingomyelin). In one contemplated use, compounds of the general formula I and II are useful in the production of sphingosine. In another contemplated use, compounds of the general formula I and II are useful in the production of a sphingofugin. Methods of manufacturing each of the above compounds are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: Avanti Polar Lipids, Inc.
    Inventor: Avanti Polar Lipids, Inc.
  • Publication number: 20130273149
    Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Applicants: AC IMMUNE SA, AVANTI POLAR LIPIDS, INC.
    Inventors: Walter A. SHAW, Stephen W. Burgess, Shengrong Li, David T. Hickman, Maria Pilar Lopez-Deber